Saw Palmetto: The Palm Berry the Prostate World Still Can't Agree On

The Oasis Health Journal · Submitted July 1, 2026 · 5:18 PM ET

Every man over fifty eventually meets his prostate. Not socially. It happens around three in the morning, once the gland has quietly enlarged, leaned on the plumbing, and decided the middle of the night is a fine time to visit the bathroom. Again.

Saw palmetto is the supplement men reach for when this starts. It has been the go-to prostate berry for decades. It is also one of the most argued-over supplements in the whole aisle, and the argument is genuinely unsettled, so let us have it honestly.

Saw palmetto (Serenoa repens) is a low, scrubby fan palm that carpets the southeastern United States, mostly Florida, where it is less a plant than a ground cover. The dark berries are the part with the reputation. The studied form is a fat-soluble extract, standardized, taken at 320 mg a day. The going theory is that it leans on the same enzyme the drug finasteride blocks (5-alpha-reductase), the one that converts testosterone into the more prostate-agitating DHT, with some anti-inflammatory activity on the side. Nice theory. The evidence is where it gets awkward.

The trial that looks great

In 2025, a four-way head-to-head study put standardized saw palmetto in the ring with the two standard prostate drugs. Two hundred men, four groups, twenty-four weeks. One group took saw palmetto at 320 mg, one took finasteride, one took tamsulosin, and one took a palm lipid extract called Palmex. The scorecard was maximum urinary flow, the practical measure of how much the stream has picked up.

Everybody improved. Saw palmetto raised flow by about 3.6 mL per second, roughly a 23 percent bump. Finasteride managed about 4.2, tamsulosin about 4.1. Statistically, the berry basically kept pace with the pharmaceuticals, and it did it while barely bothering anyone. On paper, a great day for a fruit.

Here is the asterisk, and it is a load-bearing one. That trial had no placebo group. Every man got an active treatment. So when all four groups got better, there is no way to separate the treatment from time, attention, and the plain fact that urinary symptoms drift around on their own. A trial with no placebo can tell you the berry kept up with the drugs. It cannot tell you the berry beat doing nothing.

The trials that say sit down

Doing nothing, as it happens, is exactly what the biggest and most rigorous saw palmetto trials keep comparing it to, with unkind results.

The STEP trial (New England Journal of Medicine, 2006) gave 225 men either 320 mg of saw palmetto or a placebo for a full year. No difference. Not on symptoms, not on flow, not on any objective measure.

The CAMUS trial (JAMA, 2011) suspected the dose was too polite, so it escalated 369 men up to 960 mg a day, triple the usual amount, across 72 weeks. Still no separation from placebo. It did, at least, leave PSA readings alone, so it is not quietly hiding anything from your bloodwork.

Then the Cochrane review, the referee of this sport, stacked up 27 randomized trials and roughly 4,600 men and concluded that saw palmetto, by itself or blended with other herbs, does not improve urinary symptoms or quality of life, short term or long term. The National Center for Complementary and Integrative Health puts it in fewer words: no better than placebo.

So why do men keep buying it

Two honest reasons. First, it is remarkably gentle. Every trial that found it did not do much also found it did not do much harm, with mild stomach upset about the worst of it. Compare that to the drugs it lines up against. Finasteride can dent libido, cause erectile trouble, and lower testosterone. Tamsulosin is well known for scrambling ejaculation. The 2025 head-to-head confirmed the obvious, that saw palmetto arrived with far fewer of those complaints. Of course, being 'well tolerated' is a lower bar to clear when a treatment may not be doing much to begin with. That is the deadpan version of the trade-off.

Second, symptoms are personal. Placebo response in urinary complaints is real and sometimes sizable, which is not an insult to anyone. If a cheap, safe, gentle berry takes the edge off the 3 a.m. commute, and a doctor has ruled out the serious causes, that is a reasonable thing to try with clear eyes and modest expectations.

If you want to test it, our shelf carries standardized saw palmetto at the studied 320 mg, plus fuller prostate blends that pair it with selenium and zinc, two minerals the prostate actually puts to work. None of these are cures. They are options, described plainly.

One note on how we operate. Prostate formulas are only as good as the oils inside them, and oils turn rancid when bottles sit around. We blend professional-grade formulas fresh per order instead of aging inventory on a warehouse shelf, which is why our shipping takes a beat longer and our potency is still intact when the bottle reaches you. The berry can be old. The bottle should not be.

This article is for education only and is not medical advice. New or changing urinary symptoms, and especially any blood in the urine or an inability to pass it at all, need a clinician and not a berry. Talk with a qualified professional before starting saw palmetto, particularly if you take blood thinners or have surgery coming up.

Sources

1. Comparative Study of the Efficacy and Tolerability of Palmex (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia (2025)
2. Bent et al., Saw Palmetto for Benign Prostatic Hyperplasia, the STEP trial (New England Journal of Medicine, 2006)
3. Barry et al., Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms, the CAMUS trial (JAMA, 2011)
4. Cochrane for Clinicians: Saw Palmetto for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (American Family Physician, 2024)
5. Saw Palmetto: Usefulness and Safety (National Center for Complementary and Integrative Health)
6. Finasteride, not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men with Benign Prostatic Hyperplasia (2015)